SpineCraft Announces U.S. FDA 510(k) Clearance of Comprehensive ORIO-3D Trabecular Interbody Platform
Westmont, Illinois, May 11, 2026, / OrthoSpineNews / – SpineCraft, a US-based spine surgery systems developer and manufacturer, announces FDA 510(k) clearance of the ORIO-3D Interbody Platform, a comprehensive portfolio of trabecular 3D-printed titanium implants to support spinal fusion for various surgical approaches, targeting the USD 3.4 billion Interbody Fusion Device market size (2026).
The ORIO-3D Trabecular design represents a significant step forward in fusion technology. Implants are engineered with a biomimetic pore structure intended to promote osseointegration & early biologic fixation, and incorporate a unique architecture designed for low stiffness and optimal distribution of mechanical loads across the vertebral endplates. By promoting more uniform load sharing and with added benefit of lower stiffness, implants in the ORIO-3D platform are intended to help mitigate potential subsidence risk and support the maintenance of intervertebral height and segmental alignment.
With clear clinical differentiation, SpineCraft is well positioned to drive adoption and capture share in a large and expanding market.
About SpineCraft
SpineCraft is an innovative medical device company focused on developing, manufacturing and marketing a complete portfolio of outcome-driven spine surgery systems that provide comprehensive spine care for patients with spine deformities, complex spine problems, degenerative spine conditions and spine trauma. For more information, please visit http://www.spinecraft.com